Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial (Q77535813)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

title

Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

H D White

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

8B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

57P-62P

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Thrombolysis for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Reactivation of unstable angina after the discontinuation of heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Should all occluded infarct-related arteries be opened?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Is heparin of value in the management of acute myocardial infarction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

A comparison of reteplase with alteplase for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Issues Regarding the Use of Heparin Following Streptokinase Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900663-8

10.1016/S0002-9149(98)00663-8

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809893%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference